The largest international vaccine study to date has found that COVID vaccines from Pfizer, Moderna and AstraZeneca have been linked to heart, brain and blood disorders.
Feb 21
Written By Chris Lynch
UPDATED: With comment from Auckland University Associate Professor Helen Petousis-Harris
But the Co-Director of the Global Vaccine Data Network said the risks were still “very small.”
The Auckland University hosted Global Vaccine Data Network assessed 13 neurological, blood, and heart related medical conditions to see if there was a greater risk of them occurring after receiving a Covid-19 vaccine.
It’s the latest of eight studies in the Global COVID Vaccine Safety (GCoVS) Project.
The data was sourced from information from 99 million people from 10 collaborator sites across eight countries.
The study identified the “pre-established safety signals” for myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the thin sac covering the heart) after mRNA vaccines, and Guillain-Barré syndrome (muscle weakness and changed sensation (feeling), and cerebral venous sinus thrombosis (type of blood clot in the brain) after viral vector vaccines.
“Possible safety signals for transverse myelitis (inflammation of part of the spinal cord) after viral vector vaccines and acute disseminated encephalomyelitis (inflammation and swelling in the brain and spinal cord) after viral vector and mRNA vaccines were identified.”
A large cohort study of 23.1 million residents across four Nordic countries revealed an increased risk of myocarditis among young males aged 16–24 years, based on 4–7 excess events in 28 days per 100,000 vaccinees after a second dose of the Pfizer BioNtech vaccine, and between 9 and 28 per 100,000 vaccinees after a second dose of Moderna COVID-19 vaccine.
The conclusion of this study was “this multi-country analysis confirmed pre-established safety signals for myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis. Other potential safety signals that require further investigation were identified.”
Similarly, studies from British Columbia, Canada reported cases of myocarditis to be higher among those receiving a second dose compared with a third dose, and for those who received a second dose of the Moderna COVID-19 vaccine compared with the Pfizer BioNtech.
These findings were further investigated by the GVDN site in Victoria, Australia.
Their study and results are described in the accompanying paper.
Results are available for public review on GVDN’s interactive data dashboards.
These studies look at all people who received a vaccine and examine if there is a greater risk for developing a medical condition in various time periods after getting a vaccine compared with a period before the vaccine became available.
In a statement, Lead author Kristýna Faksová of the Department of Epidemiology Research, Statens Serum Institute, Copenhagen remarked that use of a common protocol and aggregation of the data through the GVDN makes studies like this possible.
“The size of the population in this study increased the possibility of identifying rare potential vaccine safety signals.
“Single sites or regions are unlikely to have a large enough population to detect very rare signals.”
Auckland University Associate Professor Helen Petousis-Harris, and Co-Director, Global Vaccine Data Network said “by making the data publicly available, we are able to support greater transparency, and stronger communications to the health sector and public.”
GVDN Co-Director Dr. Steven Black said, “GVDN supports a coordinated global effort to assess vaccine safety and effectiveness so that vaccine questions can be addressed in a more rapid, efficient, and cost-effective manner.
“We have a number of studies underway to build upon our understanding of vaccines and how we understand vaccine safety using big data.”
The research paper said “overall risk–benefit evaluations of vaccination should take the risk associated with infection into account, as multiple studies demonstrated higher risk of developing the events under study, such as GBS, myocarditis, or ADEM, following SARS-CoV-2 infection than vaccination.”
The Ministry of Health has been approached for comment.
Helen Petousis-Harris told Chris Lynch Media “the issue with myocarditis and the thrombosis events were identified soon after the vaccines came into use and the WHO, among other authorities, raised the alert early in 2021.
“The risk of these events following the vaccine is very small and even large clinical trials are too small to identify such rare events.
The risk after vaccine is far smaller than that associated with infection with the virus and vaccinated people have lower risks for these outcomes than unvaccinated.”
Petousis-Harris said “the evidence strongly supports the benefit of booster doses for those who they are recommended.
“The vaccine most commonly used in New Zealand is well established to be associated with a small risk of heart inflammation.
“The other conditions are related to viral vector vaccines. The ADEM and TM has been followed up using an appropriate method to investigate association. This is published in the same issue of the Journal. indicated no increased risk following Pfizer mRNA vaccine.”
Martin comments: Petousis-Harris was quick to pounce on Lynch’s article. For those that do not know, she is a staunch defender and advocate of the Pfizer mRNA injection and has been since Day One of the rollout. Back then, and up until very recently, the “safe and effective” motto was her battle-cry. Now she’s backpedaling with the “benefits outweigh the risks” fallback defence. Now she can no longer deny those risks she’s in full-flight damage control.
Petousis-Harris’s claim “The risk after vaccine is far smaller than that associated with infection with the virus and vaccinated people have lower risks for these outcomes than unvaccinated.” Had me in stitches. Personal experience strongly indicates quite the reverse: The vaccinated are seemingly stuck in an endless merry-go-round of re-infection PLUS the cardiac issues. Meanwhile the unvaccinated members of my sphere of association seem to be largely fit and well and benefitting from their natural immunity.
Get your copy from our Online Store or your local book and magazine retailer
Australian Retail Locations » Uncensored Publications Limited
New Zealand Retail Locations » Uncensored Publications Limited
As censorship heats up and free thought becomes an increasingly rare commodity, we appeal to our readers to support our efforts to reach people with information now being censored elsewhere. In the last few years, Uncensored has itself been censored, removed from the shelves of two of our biggest NZ retailers – Countdown Supermarkets and Whitcoulls Bookstores – accounting for 74% of our total NZ sales.
You can help keep the Free Press alive by subscribing and/or gifting a subscription to your friends and relatives.
